InspireMD Shares CGuard(TM) EPS Video Testimonials from European Key Opinion Leaders

TEL AVIV, ISRAEL--(Marketwired - Aug 22, 2017) - InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from several European key opinion leaders on its website: http://www.inspiremd.com/en/kol-testimonials/

Featured testimonials include:

• Dr. Alberto Cremonesi, Chief of the Cardiovascular Department at Maria Cecilia Hospital, Cotignola, Italy
  
  
• Dr. Antonio Moreno, Chief Medical Officer of Endovascular Intervention World MEDICA, Madrid, Spain
  
  
• Dr. Bernhard Reimers, Clinical and Invasive Cardiology Unit Director at Humanitas Research Hospital, Milan, Italy
  
  
• Prof. Ralf Kolvenbach, Head of the Cardiovascular Diseases Department, Medical Director of the Catholic Hospitals, Duesseldorf, Germany
  
  
• Prof. Piotr Musialek, Jagiellonian University Department of Cardiac & Vascular Diseases, Krakow, Poland
  
  

James Barry, PhD, Chief Executive Officer of InspireMD, commented, "We are honored that such respected clinicians from the fields of vascular surgery, interventional cardiology and interventional neuroradiology across Europe are willing to publicly endorse our very promising technology. These testimonials provide detailed and diverse clinical views on the advantages of the CGuard Embolic Prevention System, as described by those who use it routinely in their daily practices to improve patient outcomes."

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.